Volume 11 Supplement 2
Identification of novel ligands interacting with kappa opioid receptors
© Spetea et al; licensee BioMed Central Ltd. 2011
Published: 5 September 2011
The κ opioid (KOP) receptor belongs to the family of seven transmembrane G protein-coupled receptors (GPCRs) and it plays a significant role in a broad range of physiological functions. Stimulation of the KOP receptor results in analgesic actions, and KOP agonists appear to have some advantages over the μ opioid (MOP) receptor agonists. Inhibiting KOP receptors is proposed to be useful for treating addiction and stress-related conditions, such as depression and anxiety. The pharmacology of currently available KOP antagonists shows a delay in onset of action and an extremely long duration of action in vivo, which might limit their therapeutic application. The search for new ligands with potent biological activities, particularly as potential novel therapeutic agents, utilizing computational and synthetical approaches, is a key goal of life science research and drug development. Herein, we present the in silico, in vitro and in vivo profiles of new molecular scaffolds as novel KOP receptor ligands.
LigandScout and Catalyst softwares were used to generate and validate a merged feature ligand-based 3D pharmacophore model for KOP receptors. Biological activities were evaluated in in vitro opioid receptor binding and [35S]GTPγS functional assays. Antinociceptive properties were assessed in mice using the writhing test.
The integrated computational screening strategy has led to the discovery of sewarine as KOP receptor ligand. This phenolic alkaloid from the plant Rhazya stricta binds with high selectivity to the KOP receptor and shows antagonist activity. A comprehensive SAR analysis on several analogues was pursued and primary chemical features responsible for KOP activity have been identified. Combining synthetical and pharmacological methodologies, two phenolic molecules were identified as novel highly selective ligands interacting with KOP receptors, and displaying full agonist or partial agonist properties, respectively. Dose-dependent and nor-BNI-sensitive antinociceptive effects were produced by the KOP agonist after subcutaneous administration to mice, exhibiting a potency comparable to that of U-50,488.
This study uncovers new classes of ligands interacting with KOP receptors and sharpens the understanding of ligand-receptor interactions, thus increasing the chance of developing useful clinical agents among KOP ligands.
Supported by the Austrian Science Fund (FWF: TRP 19-B18) and National Institute on Drug Abuse (NIDA: N01DA-1-8816).
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.